Answers are grounded in this paper and cite their sources.
Human cytomegalovirus (HCMV) is a member of the Betaherpesvirinae subfamily (Herpesviridae family), that, following primary infection, is able to establish latency in host tissues and may reactivate in conditions of immunosuppression. In solid organ transplant recipients, the incidence of CMV infection and disease varies according to the transplanted organ and is particularly high in transplantation (LT), reaching 40-50% incidence. Lung is a CMV latency site and in LT, viral reactivation has been associated with direct (i.e. organ and systemic infection/disease) and indirect effects (including acute rejection and chronic allograft dysfunction). The clinical importance of CMV has grown in parallel with the increasing number of solid organ transplant recipients. Symptoms related to CMV disease and the prevention of CMV infection show variation among different patient populations, on the type of transplant and the intensity of immunosuppression. Treatment and prevention of CMV infection have assumed increasing importance in lung transplant recipients management relative to the mortality morbidity and, on the other hand, to the availability of effective antiviral agents as well as new diagnostic techniques and the prophylaxis, diagnosis, and treatment of CMV infections. In lung transplant recipients management is with experience and we are living the sunrise of a new personalized or tailored management era matching, almost in real time, infection, diagnosis, immunity status and therapy.
No takes yet. Share an insight, caveat, or question.
Paolo Solidoro (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: